Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 421 participants.

Also called NCT01456195

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 421 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01456195
  • EudraCT 2011-002741-35
  • WHO UTN U1111-1124-2154
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Bulgaria, Guatemala, Hungary, Mexico, Slovakia, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01456195. Randomized; quadruple masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-07 (actual). Results posted on 2016-04-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
Fasiglifam
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct01456195
Content hash
37e7c755cee59c4623f5d619eb53b07a99c328b2eb7d6b7f9d7f53b9363986c1